These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 32986290)

  • 21. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural compounds from freshwater mussels disrupt fungal virulence determinants and influence fluconazole susceptibility in the presence of macrophages in
    Gutierrez-Gongora D; Woods M; Prosser RS; Geddes-McAlister J
    Microbiol Spectr; 2024 Mar; 12(3):e0284123. PubMed ID: 38329361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colony and Single Cell Level Analysis of the Heterogeneous Response of
    Altamirano S; Simmons C; Kozubowski L
    Front Cell Infect Microbiol; 2018; 8():203. PubMed ID: 29971221
    [No Abstract]   [Full Text] [Related]  

  • 24. Physiological Differences in Cryptococcus neoformans Strains
    Grossman NT; Casadevall A
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031206
    [No Abstract]   [Full Text] [Related]  

  • 25. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
    Nascimento E; Vitali LH; Kress MRVZ; Martinez R
    Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Antivirulence Approach for Preventing Cryptococcus neoformans from Crossing the Blood-Brain Barrier via Novel Natural Product Inhibitors of a Fungal Metalloprotease.
    Aaron PA; Vu K; Gelli A
    mBio; 2020 Jul; 11(4):. PubMed ID: 32694141
    [No Abstract]   [Full Text] [Related]  

  • 27. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii.
    Vu K; Gelli A
    Med Mycol; 2010 Mar; 48(2):255-62. PubMed ID: 19572230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of sertraline against Cryptococcus neoformans: in vitro and in vivo assays.
    Treviño-Rangel Rde J; Villanueva-Lozano H; Hernández-Rodríguez P; Martínez-Reséndez MF; García-Juárez J; Rodríguez-Rocha H; González GM
    Med Mycol; 2016 Mar; 54(3):280-6. PubMed ID: 26705833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular characterization and antifungal susceptibility testing of Cryptococcus neoformans sensu stricto from southern Brazil.
    Herkert PF; Meis JF; Lucca de Oliveira Salvador G; Rodrigues Gomes R; Aparecida Vicente V; Dominguez Muro M; Lameira Pinheiro R; Lopes Colombo A; Vargas Schwarzbold A; Sakuma de Oliveira C; Simão Ferreira M; Queiroz-Telles F; Hagen F
    J Med Microbiol; 2018 Apr; 67(4):560-569. PubMed ID: 29461182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreasing fluconazole susceptibility of clinical South African Cryptococcus neoformans isolates over a decade.
    Naicker SD; Mpembe RS; Maphanga TG; Zulu TG; Desanto D; Wadula J; Mvelase N; Maluleka C; Reddy K; Dawood H; Maloba M; Govender NP;
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008137. PubMed ID: 32231354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cryptococcus neoformans isolates from Yaoundé human immunodeficiency virus-infected patients exhibited intra-individual genetic diversity and variation in antifungal susceptibility profiles between isolates from the same patient.
    Kammalac Ngouana T; Drakulovski P; Krasteva D; Kouanfack C; Reynes J; Delaporte E; Boyom FF; Mallié M; Bertout S
    J Med Microbiol; 2016 Jul; 65(7):579-589. PubMed ID: 27100672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brilacidin, a novel antifungal agent against
    Diehl C; Pinzan CF; de Castro PA; Delbaje E; García Carnero LC; Sánchez-León E; Bhalla K; Kronstad JW; Kim D-g; Doering TL; Alkhazraji S; Mishra NN; Ibrahim AS; Yoshimura M; Vega Isuhuaylas LA; Pham LTK; Yashiroda Y; Boone C; Dos Reis TF; Goldman GH
    mBio; 2024 Jul; 15(7):e0103124. PubMed ID: 38916308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.
    Perkins A; Gomez-Lopez A; Mellado E; Rodriguez-Tudela JL; Cuenca-Estrella M
    J Antimicrob Chemother; 2005 Dec; 56(6):1144-7. PubMed ID: 16282208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Peptide from Budding Yeast GAPDH Serves as a Promising Antifungal against Cryptococcus neoformans.
    Zhang Y; Zhou L; Liu Y; Zhao X; Lian X; Zhang J; Zhao D; Wang Y; Zhong J; Wang J; Wang H; Wang L; Fu YV
    Microbiol Spectr; 2022 Feb; 10(1):e0082621. PubMed ID: 35019693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
    Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
    J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antifungal activity of peptide MSI-1 against Cryptococcus neoformans infection in vitro and in murine cryptococcal meningoencephalitis.
    Ma L; Wei S; Ye X; Xu P; Chen H; Liu Z; Zhou C
    Peptides; 2020 Aug; 130():170334. PubMed ID: 32504765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antifungal Activity, Antibiofilm and Association Studies with O-Alkylamidoximes against Cryptococcus spp.
    de Castro Teixeira AP; Fernandes Queiroga Moraes G; de Oliveira RJ; Silva Santos C; Alves Caiana RR; Rufino de Freitas JC; Vasconcelos U; de Oliveira Pereira F; Oliveira Lima I
    Chem Biodivers; 2023 Mar; 20(3):e202200539. PubMed ID: 36730650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rise and fall of Caspofungin: the current status of Caspofungin as a treatment for
    Aguiar TK; Costa AC; Neto NA; Brito DM; Freitas CD; Neto JM; Mesquita FP; Souza PF
    Future Microbiol; 2024; 19(7):621-630. PubMed ID: 38497911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro antifungal susceptibility profiles of Cryptococcus species isolated from HIV-associated cryptococcal meningitis patients in Zimbabwe.
    Nyazika TK; Herkert PF; Hagen F; Mateveke K; Robertson VJ; Meis JF
    Diagn Microbiol Infect Dis; 2016 Nov; 86(3):289-292. PubMed ID: 27608538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotypic diversity and antifungal susceptibility of Cryptococcus neoformans isolates from paediatric patients in China.
    Hong N; Chen M; Xu N; Al-Hatmi AMS; Zhang C; Pan WH; Hagen F; Boekhout T; Xu J; Zou XB; Liao WQ
    Mycoses; 2019 Feb; 62(2):171-180. PubMed ID: 30341799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.